(GALE) Galenica Sante - Ratings and Ratios
Exchange: SW • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0360674466
GALE: Pharmacy Services, Medications, Healthcare Products
Galenica Sante AG (SW:GALE) is a Swiss-based healthcare service provider with a diverse portfolio of offerings across Switzerland and international markets. The company operates through two primary business segments: Products & Care and Logistics & IT. The Products & Care division manages a network of pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, catering to both retail and specialty pharmacy needs through mediservice. This segment also provides home treatment medications and develops, markets, and distributes healthcare services and products through various channels. Additionally, the division focuses on patient-centric solutions, including medication management and adherence programs.
The Logistics & IT segment specializes in pre-wholesale services for pharmaceutical and healthcare companies, offering storage, distribution, and debt collection solutions. It also provides a master data system for the healthcare market, develops management solutions, and offers group-wide IT services. This segment distributes former Viatris OTC products and publishes technical information on pharmaceutical products in both print and electronic formats. Galenica Sante AG, founded in 1927 and headquartered in Bern, Switzerland, has established itself as a key player in healthcare distribution and services. The companys integrated approach combines logistics, IT, and healthcare services to support both providers and patients.
Over the next three months, Galenica Sante AG is expected to maintain its upward momentum, with the SMA 20 and SMA 50 indicating a bullish trend. The stocks last price of 84.05 CHF, combined with an ATR of 1.67, suggests moderate volatility. The forward P/E of 20.79 and P/B of 2.70 indicate a relatively valued stock with potential for further growth. The companys focus on integrated healthcare solutions and its strong market position in Switzerland are likely to support its performance. The 3-month price target is projected to range between 82.00 CHF and 86.50 CHF, with potential upside driven by continued operational efficiency and market expansion.
Additional Sources for GALE Stock
GALE Stock Overview
| Market Cap in USD | 5,287m |
| Sector | Healthcare |
| Industry | Medical Distribution |
| GiC Sub-Industry | Health Care Distributors |
| IPO / Inception |
GALE Stock Ratings
| Growth Rating | 58.6 |
| Fundamental | 66.4 |
| Dividend Rating | 51.1 |
| Rel. Strength | 28.8 |
| Analysts | - |
| Fair Price Momentum | 88.43 CHF |
| Fair Price DCF | 74.30 CHF |
GALE Dividends
| Dividend Yield 12m | 1.42% |
| Yield on Cost 5y | 1.82% |
| Annual Growth 5y | 4.10% |
| Payout Consistency | 93.4% |
GALE Growth Ratios
| Growth Correlation 3m | 42.2% |
| Growth Correlation 12m | 83.3% |
| Growth Correlation 5y | 86.6% |
| CAGR 5y | 6.56% |
| CAGR/Max DD 5y | 0.33 |
| Sharpe Ratio 12m | 1.57 |
| Alpha | 19.81 |
| Beta | -0.010 |
| Volatility | 21.05% |
| Current Volume | 90k |
| Average Volume 20d | 96.4k |
As of May 09, 2025, the stock is trading at CHF 86.95 with a total of 89,992 shares traded.
Over the past week, the price has changed by +0.23%, over one month by +8.35%, over three months by +7.48% and over the past year by +23.52%.
Yes, based on ValueRay Fundamental Analyses, Galenica Sante (SW:GALE) is currently (May 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 66.36 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GALE as of May 2025 is 88.43. This means that GALE is currently overvalued and has a potential downside of 1.7%.
Galenica Sante has no consensus analysts rating.
According to ValueRays Forecast Model, GALE Galenica Sante will be worth about 95.5 in May 2026. The stock is currently trading at 86.95. This means that the stock has a potential upside of +9.84%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 80.3 | -7.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 95.5 | 9.8% |